← Return to Anyone on Pluvicto (Lu 177), a new drug for prostate cancer?

Discussion

Anyone on Pluvicto (Lu 177), a new drug for prostate cancer?

Prostate Cancer | Last Active: Feb 27 9:46am | Replies (171)
Comment receiving replies
@firespooks

I’m on my second recurrence for prostate cancer. My PSA is at 0.63. Has anyone out there have that new treatment of Radiopharmacuticles ? It’s an injection of liquid radiation that targets just the cancer cells. I was just wondering of the results and where to have it done. Thank you Stephen.

Jump to this post

Replies to "I’m on my second recurrence for prostate cancer. My PSA is at 0.63. Has anyone out..."
Colleen Young, Connect Director | @colleenyoung | Oct 27, 2022

@firespooks, I moved your post to this existing discussion about new 177Lu-PSMA-617 radiopharmaceutical here:
- Anyone on Pluvicto (Lu 177), a new drug for prostate cancer? https://connect.mayoclinic.org/discussion/any-one-on-pluvecto-a-relatively-new-drug/

Since being approved in March 2022, the treatment has been named Pluvicto (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617).

VIEW AND REPLY